Axsome Therapeutics (AXSM) Tops Q1 EPS by 8c

Axsome Therapeutics (NASDAQ: AXSM) reported Q1 EPS of ($1.22), $0.08 better than the analyst estimate of ($1.30). Revenue for the quarter came in at $121.46 million versus the consensus estimate of $121.58 million.

For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.

You May Also Be Interested In

• Truist: '2Q26 earnings is shaping up to be a meaningful catalyst for MDLN - in either direction'
• Knightscope reports preliminary Q2 revenue of ~$9M, up 200%
• Standard BioTools files S-4 for Treeline merger, citing 84% lymphoma ORR